Compare · ABT vs RPRX
ABT vs RPRX
Side-by-side comparison of Abbott Laboratories (ABT) and Royalty Pharma plc (RPRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and RPRX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $158.63B, about 4.9x RPRX ($32.17B).
- Over the past year, ABT is down 31.7% and RPRX is up 67.4% - RPRX leads by 99.1 points.
- Both names hit the wire about 5 times in the past 4 weeks.
- ABT has more recent analyst coverage (25 ratings vs 12 for RPRX).
- Company
- Abbott Laboratories
- Royalty Pharma plc
- Price
- -
- -
- Market cap
- $158.63B
- $32.17B
- 1M return
- +5.60%
- +10.25%
- 1Y return
- -31.73%
- +67.39%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- News (4w)
- 5
- 5
- Recent ratings
- 25
- 12
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Royalty Pharma plc
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 45 marketed therapies and 9 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Latest ABT
- New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis
- SEC Form SD filed by Abbott Laboratories
- Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes
- ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening
- Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026
- SEC Form 4 filed by EXECUTIVE VICE PRESIDENT Moreland Mary K
- SEC Form SCHEDULE 13G filed by Abbott Laboratories
- SEC Form 10-Q filed by Abbott Laboratories
- Director Conroy Kevin T was granted 2,286 units of Common shares without par value, increasing direct ownership by 2% to 133,737 units (SEC Form 4)
- New insider Conroy Kevin T claimed ownership of 131,451 units of Common shares without par value (SEC Form 3)
Latest RPRX
- SEC Form 8-K filed by Royalty Pharma plc
- Royalty Pharma to present at the Goldman Sachs 47th Annual Global Healthcare Conference
- EVP & CFO Coyne Terrance P. sold $3,476,116 worth of Class A Ordinary Shares (64,399 units at $53.98) as part of a pre-agreed trading plan (SEC Form 4)
- Royalty Pharma plc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation
- EVP, Research & Investments Urist Marshall sold $721,838 worth of Class A Ordinary Shares (13,684 units at $52.75) as part of a pre-agreed trading plan, decreasing direct ownership by 43% to 18,197 units (SEC Form 4)
- Director Norden Gregory sold $161,385 worth of Class A Ordinary Shares (3,045 units at $53.00) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 191,803 units (SEC Form 4)
- EVP, Research & Investments Urist Marshall sold $726,137 worth of Class A Ordinary Shares (13,684 units at $53.06) as part of a pre-agreed trading plan, decreasing direct ownership by 30% to 31,881 units (SEC Form 4)
- SEC Form 144 filed by Royalty Pharma plc
- SEC Form 13F-NT filed by Royalty Pharma plc
- Amendment: SEC Form SCHEDULE 13G/A filed by Royalty Pharma plc